On February 16, the Shenzhen Stock Exchange issued a decision to terminate the review of the initial public offering and listing of Yantai MyPlex International Biopharmaceutical Co., Ltd. (hereinafter referred to as MyPlex) on the Growth Enterprise Market. Previously, MyPlex's IPO application was accepted on September 28, 2022, and passed the meeting on June 16, 2023, but the company finally chose to withdraw its application due to failure to submit registration materials within the prescribed time.

According to the information, MyPlex was established in 2013 and is a CDMO (contracted research and development and production of pharmaceuticals) company focusing on the field of biopharmaceuticals, focusing on providing CDMO services for monoclonal antibodies, bispecific antibodies, polyspecific antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins and other biopharmaceuticals.

The reporter of "Daily Economic News" noticed that MyBio was found to have major errors in its application materials during the first round of audit inquiries. Specifically, there were errors in the calculation of non-recurring gains and losses in 2019, which led to major errors in the disclosure of the company's net profit attributable to the parent company's shareholders after deducting non-recurring gains and losses in the company's prospectus, the listing sponsorship letter issued by the sponsor, and the "Financial Report and Audit Report" and "Non-recurring Profit and Loss Statement Attested by Certified Public Accountants" issued by the reporting accountant, resulting in the incorrect disclosure of net profit of -452 million yuan, with a difference of 386 million yuan.

It is worth noting that MyBio's financial and other relevant departments, as well as intermediary institutions Huatai United Securities and Ernst & Young Huaming Accounting Firm, did not discover this series of errors. In the end, the company, the sponsor representative and the signing accountant were all warned in writing by the Shenzhen Stock Exchange.

https://finance.eastmoney.com/a/202502173321333949.html